Dr. Jonathan I. Goldstein, M.D.

Medicare patients and services

Medicare patients, 2024

105

Services billed

232

Patients’ average age

70

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 9 companies reported 68 payments worth $66,885 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in New York →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 4 companies. The companies reported $119,284 in research payments for these studies, mostly to the institutions running them.

• A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis (Ametrine-2)
  Genentech, Inc.
• A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
  AbbVie Inc. · Active, not recruiting · NCT06880744
• A study of TAK-062 in treatment of active celiac disease in participants attempting a gluten-free diet
  Takeda Pharmaceuticals U.S.A., Inc.
• TAK-279 CD/UC Ph2 OLE
  Takeda Pharmaceuticals U.S.A., Inc.
• A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1)
  F. Hoffmann-la Roche AG
• A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
  AbbVie Inc. · Active, not recruiting · NCT03006068
• A Non-Interventional Clinical Study to Evaluate Long-Term Safety and Effectiveness of HUMIRA (Adalimumab) in Pediatric Patients With Moderately to Severely Active Crohn Disease (CD)
  AbbVie Inc.
• A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to …
  Takeda Pharmaceuticals U.S.A., Inc.
• M14-533 - A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
  AbbVie Inc.
• A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
  AbbVie Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Gastroenterology clinicians in Rochester

• Maisa I. Abdalla, M.D.
• Smith Agyingi, MD
• Bandar Aljudaibi
• Muddusir M. Ayaz, M.D.
• Anthony V. Baratta JR., M.D.
• Tanya S. Bruckel, MD
• Kevin Casey, M.D.
• Janice Cheong, M.D.